Statin+Ezetimibe/Hybutimibe compound
PreclinicalSmall molecule
Statin+Ezetimibe/Hybutimibe compound is one of 49 small molecule programs targeting Acute Coronary Syndrome. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
54 competitors in Acute Coronary Syndrome
#DrugCompanyPhaseTrials
1Plavix
SanofiApproved
Brilinta
AstraZenecaApproved
Crestor
AstraZenecaApproved
Bayer Aspirin
BayerApproved
Colcrys
Jazz PharmaceuticalsApproved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Leqvio
NovartisApproved
Praluent
RegeneronApproved
Lescol
NovartisApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- YYun Dai Chen